Literature DB >> 24841166

Bladder cancer: bladder preservation--learning what we don't know.

Maha Hussain1, Dan Theodorescu2.   

Abstract

Bladder preservation for patients with muscle-invasive bladder cancer has the potential to offer a quality-of-life advantage, but owing to the lack of randomized trials oncological equivalence to surgery has not been demonstrated. A new article provides a comprehensive overview of the current status of this procedure, but raises timely and important questions.

Entities:  

Mesh:

Year:  2014        PMID: 24841166     DOI: 10.1038/nrurol.2014.102

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN: 1759-4812            Impact factor:   14.432


  10 in total

1.  Gene expression in the urinary bladder: a common carcinoma in situ gene expression signature exists disregarding histopathological classification.

Authors:  Lars Dyrskjøt; Mogens Kruhøffer; Thomas Thykjaer; Niels Marcussen; Jens L Jensen; Klaus Møller; Torben F Ørntoft
Journal:  Cancer Res       Date:  2004-06-01       Impact factor: 12.701

2.  Prediction of stage, grade, and survival in bladder cancer using genome-wide expression data: a validation study.

Authors:  Martin Lauss; Markus Ringnér; Mattias Höglund
Journal:  Clin Cancer Res       Date:  2010-08-24       Impact factor: 12.531

3.  A cell of origin gene signature indicates human bladder cancer has distinct cellular progenitors.

Authors:  Garrett M Dancik; Charles R Owens; Kenneth A Iczkowski; Dan Theodorescu
Journal:  Stem Cells       Date:  2014-04       Impact factor: 6.277

4.  Cancer incidence after localized therapy for prostate cancer.

Authors:  Kihyuck Moon; George J Stukenborg; Jessica Keim; Dan Theodorescu
Journal:  Cancer       Date:  2006-09-01       Impact factor: 6.860

5.  Cyclophilin B expression is associated with in vitro radioresistance and clinical outcome after radiotherapy.

Authors:  Paul D Williams; Charles R Owens; Jaroslaw Dziegielewski; Christopher A Moskaluk; Paul W Read; James M Larner; Michael D Story; William A Brock; Sally A Amundson; Jae K Lee; Dan Theodorescu
Journal:  Neoplasia       Date:  2011-12       Impact factor: 5.715

Review 6.  Critical analysis of bladder sparing with trimodal therapy in muscle-invasive bladder cancer: a systematic review.

Authors:  Guillaume Ploussard; Siamak Daneshmand; Jason A Efstathiou; Harry W Herr; Nicholas D James; Claus M Rödel; Shahrokh F Shariat; William U Shipley; Cora N Sternberg; George N Thalmann; Wassim Kassouf
Journal:  Eur Urol       Date:  2014-02-26       Impact factor: 20.096

7.  Assessment of quality of life after cystectomy or conservative therapy for patients with infiltrating bladder carcinoma. A survey by a self-administered questionnaire.

Authors:  O Caffo; G Fellin; U Graffer; L Luciani
Journal:  Cancer       Date:  1996-09-01       Impact factor: 6.860

8.  A 20-gene model for molecular nodal staging of bladder cancer: development and prospective assessment.

Authors:  Steven Christopher Smith; Alexander Spyridon Baras; Garrett Dancik; Yuanbin Ru; Kuan-Fu Ding; Christopher A Moskaluk; Yves Fradet; Jan Lehmann; Michael Stöckle; Arndt Hartmann; Jae K Lee; Dan Theodorescu
Journal:  Lancet Oncol       Date:  2011-01-20       Impact factor: 41.316

Review 9.  The COXEN principle: translating signatures of in vitro chemosensitivity into tools for clinical outcome prediction and drug discovery in cancer.

Authors:  Steven C Smith; Alexander S Baras; Jae K Lee; Dan Theodorescu
Journal:  Cancer Res       Date:  2010-02-16       Impact factor: 12.701

10.  Prospective randomized controlled trial of robotic versus open radical cystectomy for bladder cancer: perioperative and pathologic results.

Authors:  Jeff Nix; Angela Smith; Raj Kurpad; Matthew E Nielsen; Eric M Wallen; Raj S Pruthi
Journal:  Eur Urol       Date:  2009-10-20       Impact factor: 20.096

  10 in total
  1 in total

1.  Effect of internal iliac artery chemotherapy after transurethral resection of bladder tumor for muscle invasive bladder cancer.

Authors:  Jianxing Li; Qi Wang; Bo Xiao; Xin Zhang
Journal:  Chin J Cancer Res       Date:  2014-10       Impact factor: 5.087

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.